A5035110996- Bladder and Urothelial Cancer Treatments
- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- Fibroblast Growth Factor Research
- Renal cell carcinoma treatment
- Vasculitis and related conditions
- Urinary and Genital Oncology Studies
- Neonatal Health and Biochemistry
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pediatric Urology and Nephrology Studies
- Ocular Diseases and Behçet’s Syndrome
- Urinary Tract Infections Management
- Urticaria and Related Conditions
- Systemic Lupus Erythematosus Research
- Abdominal Surgery and Complications
- Renal Diseases and Glomerulopathies
- Pneumothorax, Barotrauma, Emphysema
- Clinical Reasoning and Diagnostic Skills
Spanish National Cancer Research Centre
2023
Hospital General de Granollers
2014-2020
Bladder cancer is a highly prevalent tumor, requiring the urgent development of novel therapies, especially for locally advanced and metastatic disease. Nintedanib potent antifibrotic angio-kinase inhibitor, which has shown clinical efficacy in combination with chemotherapy patients muscle-invasive bladder cancer. inhibits fibroblast growth factor receptors (FGFRs), validated targets harboring FGFR3/2 genetic alterations. Here, we aimed at studying its mechanisms action to understand therapy...
To develop and validate a prediction rule to identify well-appearing febrile infants aged ≤90 days with an abnormal urine dipstick at low risk of invasive bacterial infections (IBIs, bacteraemia or meningitis).
between onset of the disease and diagnostic was 7.2±5.3 days. Ethnic distribution was: Caucasian 279 patients(69.9%), North African 26 (6.5%), Amerindian 21 (5.2%), Asian 14 (3.5%) Sub-Saharan 4 (1%). Ethnicity not available in 55 (13.8%) patients. Distribution classical manifestations for KD fever 100% patients, changes extremities 40.3% (desquamation 31% them), exanthema 84.2%, conjunctival injection 79.7%, lips oral cavity 55.6% lymphadenopathy 28.8%. Other clinical findings reported...
<p>Supplementary Tables and Figures</p>
<p>Supplementary Tables and Figures</p>
<div>Abstract<p>Bladder cancer is a highly prevalent tumor, requiring the urgent development of novel therapies, especially for locally advanced and metastatic disease. Nintedanib potent anti-fibrotic angio-kinase inhibitor, which has shown clinical efficacy in combination with chemotherapy muscle invasive BC patients. inhibits Fibroblast Growth Factor receptors (FGFRs), validated targets patients harboring FGFR3/2 genetic alterations. Here, we aimed at studying its mechanisms...
<p>Supplementary Tables and Figures</p>
<p>Supplementary Tables and Figures</p>
<p>Supplementary Tables and Figures</p>
<div>Abstract<p>Bladder cancer is a highly prevalent tumor, requiring the urgent development of novel therapies, especially for locally advanced and metastatic disease. Nintedanib potent anti-fibrotic angio-kinase inhibitor, which has shown clinical efficacy in combination with chemotherapy muscle invasive BC patients. inhibits Fibroblast Growth Factor receptors (FGFRs), validated targets patients harboring FGFR3/2 genetic alterations. Here, we aimed at studying its mechanisms...
<div>Abstract<p>Bladder cancer is a highly prevalent tumor, requiring the urgent development of novel therapies, especially for locally advanced and metastatic disease. Nintedanib potent antifibrotic angio-kinase inhibitor, which has shown clinical efficacy in combination with chemotherapy patients muscle-invasive bladder cancer. inhibits fibroblast growth factor receptors (FGFRs), validated targets harboring <i>FGFR3/2</i> genetic alterations. Here, we aimed at...
<p>Supplementary Tables and Figures</p>
<div>Abstract<p>Bladder cancer is a highly prevalent tumor, requiring the urgent development of novel therapies, especially for locally advanced and metastatic disease. Nintedanib potent antifibrotic angio-kinase inhibitor, which has shown clinical efficacy in combination with chemotherapy patients muscle-invasive bladder cancer. inhibits fibroblast growth factor receptors (FGFRs), validated targets harboring <i>FGFR3/2</i> genetic alterations. Here, we aimed at...